Zhou Liping, Yang Linhong, Tilton Suzanne, Wang Jianling
PreClinical Profiling, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.
J Pharm Sci. 2007 Nov;96(11):3052-71. doi: 10.1002/jps.20913.
Increasingly, pharmaceutical and biotech companies have begun to realize the importance of obtaining solubility information in early drug discovery as it is one of the critical parameters for lead selection and optimization. This report introduces a high-throughput equilibrium solubility (HT-Eq sol) assay using a novel miniaturized shake-flask approach and streamlined HPLC analysis. The new HT-Eq sol assay, validated and optimized via a test set of 85 marketed drugs and Novartis internal compounds, shows an excellent correlation to the conventional shake-flask thermodynamic solubility data generated in-house and the equilibrium solubility results reported in literature. It therefore offers a fast, reliable and cost-effective screening tool for solubility assessment in early drug discovery, allowing for prioritization of drug candidates using aqueous solubility in conjunction with other profiling information and efficacy data. Our work demonstrates that presence of a small amount of DMSO (0.5-5%) will result in significant overstimation of equilibrium solubility (up to 6 folds). In addition, monitoring of drug dissolution process using the current approach as well as the interplay between equilibrium solubility data and those from kinetic solubility are discussed.
制药和生物技术公司越来越意识到在药物早期发现阶段获取溶解度信息的重要性,因为它是先导化合物筛选和优化的关键参数之一。本报告介绍了一种高通量平衡溶解度(HT-Eq sol)测定方法,该方法采用新型小型化摇瓶法和简化的高效液相色谱分析。通过对85种市售药物和诺华内部化合物的测试集进行验证和优化,新的HT-Eq sol测定方法与内部生成的传统摇瓶热力学溶解度数据以及文献报道的平衡溶解度结果具有良好的相关性。因此,它为药物早期发现中的溶解度评估提供了一种快速、可靠且经济高效的筛选工具,允许结合水溶性以及其他分析信息和功效数据对候选药物进行优先级排序。我们的研究表明,存在少量二甲基亚砜(DMSO,0.5 - 5%)会导致平衡溶解度显著高估(高达6倍)。此外,还讨论了使用当前方法监测药物溶解过程以及平衡溶解度数据与动力学溶解度数据之间的相互作用。